This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
IRVINE, Calif., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Shelley B. Thunen to the position of Chief Financial Officer, effective immediately. Ms. Thunen succeeds Robert J. Krist, who, as previously announced, has decided to retire. Mr. Krist will remain available to the Company to ensure a smooth transition.
John McDermott, Chairman, President and Chief Executive Officer of Endologix, said, "We are very pleased to welcome Shelley Thunen to the Endologix management team. Shelley has extensive experience serving as a public company CFO in the medical technology industry, with expertise across all areas of finance, investor relations and business development, which will be beneficial as we continue to expand our business."
Ms. Thunen's experience in the medical technology industry includes having served as Chief Financial Officer of two Nasdaq-listed companies and several private companies in the sector. Prior to joining Endologix, Ms. Thunen served as Associate General Manager of Alcon LenSx, Inc. (acquired August 2010), a wholly owned Alcon company that develops and manufactures a laser and related disposable for use in cataract surgery. Prior to the acquisition by Alcon, Ms. Thunen served as Chief Financial Officer and Vice President, Operations at that company since 2009. She also served on the LenSx Board of Directors and as chairperson of the Audit Committee from 2008 until its acquisition in 2010. Ms. Thunen was a Board Member and chairperson of the Audit Committee for eyeonics, inc., a developer and manufacturer of accommodating intraocular lenses for the treatment of cataracts, from 2007 to 2008 until eyeonics was acquired by Bausch & Lomb, a diversified ophthalmology company. From 2007 to 2009, Ms. Thunen was Chief Financial Officer of TherOx, Inc., a privately-held medical device company focused on cardiovascular therapeutics. From 2004 to 2007, Ms. Thunen was Executive Vice President and Chief Financial Officer, and from 2001 to 2004 Chief Financial Officer of IntraLase Corp., a Nasdaq-listed ophthalmology company that designs, develops and manufactures the IntraLase laser and disposable product, used in LASIK surgery. IntraLase was acquired by Advanced Medical Optics, Inc., an NYSE-listed company, in 2007.